Bicycle Therapeutics plc

We are a clinical-stage pharmaceutical company developing a novel class of medicines called Bicycle® molecules for diseases not adequately addressed by current treatments. Bicycle molecules are fully synthetic short peptides constrained into two loops, stabilizing their structure. This constraint enables high-affinity and selective target binding, making them suitable for drug development. Bicycle molecules combine the pharmacological characteristics of biologics with the manufacturing and pharmacokinetic (PK) properties of small molecules. Their relatively large surface area allows them to target areas historically difficult for non-biological approaches. Bicycle molecules are excreted by the kidney, not the liver, and have shown no significant immunogenicity to date. We use a novel and proprietary phage display screening platform to efficiently identify Bicycle molecules. This platform initially displays linear peptides on engineered bacteriophages, or phages, followed by "on-phage" cyclization with small molecule scaffolds. Our platform encodes quintillions of potential Bicycle molecules for screening and optimization into product candidates. We have used this technology to identify our current oncology candidates and plan to use it with collaborators for future candidates in other disease areas. Our internal programs focus on oncology indications with high unmet medical need. Our product candidate, nuzefatide pevedotin (formerly BT5528), is a Bicycle Drug Conjugate (BDC® molecule), where the Bicycle molecule is chemically linked to a toxin that, upon administration, cleaves from the Bicycle molecule to kill tumor cells.